newsFDA approves first once-monthly buprenorphine injection for OUD8 December 2017 | By Dr Zara Kassam (European Pharmaceutical Review)FDA approves first once-monthly buprenorphine injection, a medication-assisted treatment option for moderate-to-severe opioid use disorder...
newsEMA grants marketing authorisation for Zubsolv for opioid dependence21 November 2017 | By Dr Zara Kassam (European Pharmaceutical Review)The EMA has granted a Marketing Authorization for Zubsolv, a novel rapidly-disintegrating treatment option for opioid dependence...
newsMundipharma obtains global ex-US rights to Zubsolv30 June 2016 | By Victoria White, Digital Content ProducerOrexo’s Zubsolv (buprenorphine and naloxone sublingual tablet) is a potential new treatment option for patients with opioid dependence...
news24-week clinical study strengthens the evidence of the therapeutic value of Zubsolv for maintenance treatment of opioid dependence22 April 2015 | By Victoria WhiteOrexo has announced data from a trial assessing the long-term safety and efficacy of Zubsolv sublingual tablet for the treatment of opioid dependence...